Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity
Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two years could look like for shareholders.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next. Retatrutide, orforglipron, and a stacked oncology and neuroscience bench point to a growth runway that our proprietary model believes justifies a materially higher stock price over the next twelve months.
Our 24/7 Wall St. price target for Eli Lilly is $1,415.89, implying 19.67% upside from the current $1,183.16 quote. The recommendation is buy at 90% confidence. The model combines accelerating earnings, defensive beta, and pipeline blockbuster optionality.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $1,183.16 |
| 24/7 Wall St. Price Target | $1,415.89 |
| Upside | 19.67% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Trillion-Dollar Milestone, Then a Cool-Off
Lilly became the first pharmaceutical firm worth $1 trillion in late May, and shares are up 69.79% over the past year and 10.63% year to date. The stock is down 3.82% over the past week and sitting about 5% below the 52-week high of $1,247.66.
That pullback follows a Q2 report that was one of the cleanest earnings reports in large-cap pharma this cycle: revenue of $22.974 billion (up 47.67%), EPS of $8.38 beating expectations, and management raising FY26 revenue guidance to $85 to $87 billion.
The Case for $1,600+
The bull scenario points to $1,627.17, or 37.53% upside. Retatrutide, the triple GLP-1/GIP/glucagon agonist, produced weight loss approaching bariatric surgery levels across three positive Phase 3 trials, with a BLA submission planned for Q1 2027. AJMC called it a “trillion-dollar drug”, defensible given Lilly already owns roughly 6 out of 10 U.S. obesity prescriptions.
Foundayo, the only oral GLP-1 approved for anytime dosing, jumped from 8,000 to 36,000 prescribers in a single quarter. Add in the Medicare GLP-1 Bridge Program covering 20 million eligible Americans at $50 per month, and the analyst consensus target of $1,310.90 looks conservative.
What Could Go Wrong
The bear case pins fair value at $1,174.96, essentially flat. Risks include U.S. realized prices falling roughly 9% excluding rebate adjustments, Novo Nordisk competing for share, and manufacturing capacity constraints.
The Q2 tax rate spiked to 23.3% because of $2.78 billion in IPR&D charges from four acquisitions. Insider activity has skewed to net selling across 14 recent transactions. The IPR&D drag reflects aggressive pipeline building (Orna, Ajax, Centessa, Kelonia), and gross margin expanded to 85.8%.
How Lilly Compares to Novo Nordisk and Merck
Novo Nordisk (NYSE:NVO) trades at a forward P/E of just 14 with quarterly revenue growth of only 2.1% and earnings contracting 20.6% year over year. Lilly’s premium multiple is earned.
Merck (NYSE:MRK) offers a useful big-pharma contrast. Merck’s forward P/E is 50, with revenue growth of only 5.1% and EPS growth of negative 19.3%. Lilly’s 32x forward earnings paired with 47.67% revenue growth compares favorably on a growth-adjusted basis.
| Company | Forward P/E | Revenue Growth YoY |
|---|---|---|
| Eli Lilly | 32 | 47.67% |
| Novo Nordisk | 14 | 2.1% |
| Merck | 50 | 5.1% |
Eli Lilly Price Prediction 2026-2030
The 24/7 Wall St. model output is a buy rating at 90% confidence, with a price target of $1,415.89. Retatrutide is the tipping factor. If the BLA lands on time and the label spans obesity, sleep apnea, and osteoarthritis, the bull scenario at $1,627 becomes the base case. The thesis weakens if U.S. pricing erosion accelerates past 15% or Novo delivers a surprise oral formulation win.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $1,415.89 |
| 2027 | $1,585 |
| 2028 | $1,760 |
| 2029 | $1,910 |
| 2030 | $2,054.78 |
These projections assume Lilly executes on retatrutide’s launch and continues expanding Foundayo internationally. Significant upside or downside could result from GLP-1 competitive dynamics and U.S. drug-pricing policy.
Contact [email protected] for any questions or corrections.
Vandita Jadeja is a financial publisher with over a decade of experience writing about financial topics, including investment, savings, retirement, insurance and banking. Vandita is a Chartered Accountant who loves to debunk financial concepts for readers.
Her work has appeared on sites that include The Motley Fool, InvestorPlace, and Benzinga. She covers investing and focuses on stock picks and price prediction for 24/7 Wall St.
When not looking for the next stock investment opportunity, she can be found traveling, reading, chasing sunsets and enjoying her iced latte.
